← Back to all trials
Completed
NCT05899725
The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia
Conditions: Severe Checkpoint Inhibitor Pneumonitis
Sex: All
Ages: 15 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Peking Union Medical College Hospital
Location: Department of Respiratory Medicine, Peking Union Medical College Hospita Beijing Beijing Municipality
Summary
This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.
Eligibility Criteria
Inclusion Criteria:
1. 18 years old≤ Aged ≤80 years old.
2. Diagnosis of malignancy.
3. Malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting PD-1, PD-L1, CTLA-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy.
4. Diagnosis of grade 3 or 4 CIP: CIP severity at CTCAE grade 3 or 4.
5. Patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent.
Exclusion Criteria:
1. Predicted life expectancy\
Source: ClinicalTrials.gov (NCT05899725). StuddyBuddy aggregates publicly available trial information.
